Abstract
The loss of transcription factor AP-2α expression has been shown to associate with tumourigenicity of melanoma cell lines and poor prognosis in primary cutaneous melanoma. Altogether these findings suggest that the gene encoding AP-2α (TFAP2A) acts as a tumour suppressor in melanoma. To learn more of AP-2α’s down-regulation mechanisms, we compared the immunohistochemical AP-2α protein expression patterns with the corresponding mRNA expression detected by in situ hybridization in 52 primary melanomas. Of the 25 samples with AP-2α protein negative areas, 16 (64%) expressed mRNA throughout the consecutive section. Nine specimens (36%) contained equally mRNA- and protein-negative areas, suggesting that the loss of AP-2α protein associated with lack of the mRNA transcript. The highly AP-2α protein-positive tumours (n = 27) were concordantly mRNA positive in 25 (92.6%) cases. Thirteen primary tumours were further analysed using microsatellite markers D6S470 and D6S263 for loss of heterozygosity (LOH) of a locus harbouring TFAP2A. LOHs or chromosome 6 monosomy were found in four out of five (80%) informative AP-2α mRNA- and protein-negative tumour areas, but also within five out of 13 (38%) informative AP-2α mRNA-positive tumour areas. This chromosome region is thus suggestive of harbouring a putative tumour suppressor gene of cutaneous melanoma, but this referring specifically to TFAP2A could not be completely verified in this analysis. We conclude that a failure in post-transcriptional processing of AP-2α is a possible inactivation mechanism of AP-2α in cutaneous melanoma. Copyright 2000 Cancer Research Campaign © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen P, Ledbetter DH, Barker DF and Nakamura Y (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244: 217–221
Bar-Eli M (1997) Molecular mechanisms of melanoma metastasis. J Cell Physiol 173: 275–278
Bosher JM, Williams T and Hurst HC (1995) The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci USA 92: 744–747
Buettner R, Kannan P, Imhof A, Bauer R, Yim SO, Glockshuber R, Van Dyke MW and Tainsky MA (1993) An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2. Mol Cell Biol 13: 4174–4185
Butz K, Geisen C, Ullman A, Zentgraf H and Hoppe-Seyler F (1998) Uncoupling of p21WAF1/CIP1/SDI1mRNA and protein expression upon genotoxic stress. Oncogene 17: 781–787
Canzian F, Salovaara R, Hemminki A, Cristo P, Chadwich RB, Aaltonen LA and de-la-Chapelle A (1996) Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 56: 3331–3337
Day DA and Tuite MF (1998) Post-transcriptional gene regulatory mechanisms in eukaryocytes: an overview. J Endocrinol 157: 361–371
Dodson MK, Cliby WA, Xu HJ, DeLacey KA, Hu SX, Keeney GL, Li J, Podratz KL, Jenkins RB and Benedict WF (1994) Evidence of functional RB protein in epithelial ovarian carcinomas despite the loss of heterozygosity at RB locus. Cancer Res 54: 610–613
Foulkes WD, Ragoussis J, Stamp GWH, Allan GJ and Trowsdale J (1993) Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br J Cancer 67: 551–559
Gaynor RB, Muchard C, Xia Y, Klisak I, Mohandas T, Sparkes RS and Lusis AJ (1991) Localization of the gene for the DNA-binding protein AP-2 to human chromosome 6p22.3-pter. Genomics 10: 1100–1102
Gonzalgo ML, Bender CM, You EH, Glendening JM, Flores JF, Walker GJ, Hayward NK, Jones PA and Fountain JW (1997) Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res 57: 5336–5347
Huang S, Jean D, Luca M, Tainsky MA and Bar-Eli M (1998) Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J 17: 4358–4369
Imhof A, Schuierer M, Werner O, Moser M, Roth C, Bauer R and Buettner R (1999) Transcriptional regulation of the AP-2alpha promoter by BTEB-1 and AP-2rep, a novel wt-1/egr-related zinc finger repressor. Mol Cell Biol 19: 194–204
Isola J, De Vries S, Chu L, Chazvini S and Waldman F (1994) Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol 115: 1301–1308
Jean D, Gershenwald JE, Huang S, Luca M, Hudson MJ, Tainsky MA and Bar-Eli M (1998) Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 273: 16501–16508
Karjalainen JM, Kellokoski JK, Eskelinen MJ, Alhava EM and Kosma VM (1998) Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J Clin Oncol 16: 3584–3591
Kleijn M, Scheper GC, Voorma HO and Thomas AAM (1998) Regulation of translation initiation factors by signal transduction. Eur J Biochem 253: 531–544
Knudson AGJ (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820–823
Levine AJ and Momand J (1990) Tumor suppressor genes: the p53 and retinioblastoma sensitivity genes and gene products. Biochimica Biophysica Acta 1032: 119–136
Liu SY and Redmond TM (1998) Role of the 3′-untranslated region of RPE65 mRNA in the translational regulation of the RPE65 gene: identification of a specific translation inhibitory element. Arch Biochem Biophys 357: 37–44
Meier P, Koedood M, Philipp J, Fontana A and Mitchell PJ (1995) Alternative mRNAs encode multiple isoforms of transcription factor AP-2 during murine embryogenesis. Dev Biol 169: 1–14
Millikin D, Meese E, Vogelstein B, Witkowski C and Trent J (1991) Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res 51: 5449–5453
Mitchell PJ, Wang C and Tjian R (1987) Positive and negative regulation of transcription in vitro: enhancer-binding protein AP-2 is inhibited by SV40 T antigen. Cell 50: 847–861
Mitchell PJ, Timmons PM, Hebert JM, Rigby PW and Tjian R (1991) Transcription factor AP-2 is expressed in neural crest cell lineages during mouse embryogenesis. Genes Dev 5: 105–119
Noviello C, Courjal F and Theillet C (1996) Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletion. Clin Cancer Res 2: 1601–1606
Ohtaka-Maruyama C, Hanaoka F and Chepelinsky AB (1998) A novel alternative spliced variant of the transcription factor AP2alpha is expressed in the murine ocular lens. Dev Biol 202: 125–135
Real LM, Jimenez P, Canton J, Kirkin A, Garcia A, Abril E, Zeuthen J, Ruiz-Cabello F and Garrido F (1998) In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele. Int J Cancer 75: 317–323
Robertson GP, Coleman AB and Lugo TG (1996) Mechanisms of human melanoma cell growth and tumor suppression by chromosome 6. Cancer Res 56: 1635–1641
Sellers WR and Kaelin WGJ (1997) Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 15: 3301–3312
Slominski A, Wortsman J, Nickoloff B, McClatchey K, Mihm MC and Ross JS (1998) Molecular pathology of malignant melanoma. Am J Clin Pathol 110: 788–794
Sugg SL, Ezzat S, Rosen IB, Freeman JL and Asa SL (1998) Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metabol 83: 4116–4122
Trent JM, Stanbridge EJ, McBride HL, Meese EU, Casey G, Araujo D, Witkowski CM and Nagle RB (1990) Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science 247: 568–571
Turner BC, Zhang J, Gumbs AA, Maher MG, Kaplan L, Carter D, Glazer PM, Hurst HC, Haffty BG and Williams T (1998) Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Cancer Res 58: 5466–5472
Walker GJ, Palmer JM, Walters MK, Nancarrow DJ, Parsons PG and Hayward NK (1994) Simple tandem repeat allelic deletions confirm the preferential loss of distal chromosome 6q in melanoma. Int J Cancer 58: 203–206
Wang E, Ma W-J, Aghajanian C and Spriggs DR (1997) Posttranscriptional regulation of protein expression in human epithelial carcinoma cells by adenine-uridine-rich elements in the 3′-untranslated region of tumor necrosis factor-α messenger RNA. Cancer Res 57: 5426–5433
Williamson JA, Bosher JM, Skinner A, Sheer D, Williams T and Hurst HC (1996) Chromosomal mapping of the human and mouse homologues of two new members of the AP-2 family of transcription factors. Genomics 35: 262–264
Zeng YX, Somasundaram K and el-Deiry WS (1997) AP2 inhibits cancer cell growth and activates p21 WAF1/CIP1 expression. Nat Genet 15: 78–82
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Karjalainen, J., Kellokoski, J., Mannermaa, A. et al. Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2 α in cutaneous melanoma. Br J Cancer 82, 2015–2021 (2000). https://doi.org/10.1054/bjoc.2000.1145
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1145
Keywords
This article is cited by
-
TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF/PEDF signaling
Molecular Cancer (2014)
-
AP-2α and AP-2γ are transcriptional targets of p53 in human breast carcinoma cells
Oncogene (2006)
-
Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers
British Journal of Cancer (2003)
-
Transcription factors and other dysregulated proteins in melanoma prognosis
Current Oncology Reports (2001)